There’s a busy week ahead for pharma and biotech in Washington — and beyond. Here’s what we’re looking out for:
A week without a health care debate
Well, maybe. But with Republican efforts to replace the Affordable Care Act indefinitely sidelined, House Speaker Paul Ryan said the party is “going to move on with the rest of our agenda.” That means tax reform, which is of particular interest to the biopharma industry, whose enthusiasm for President Trump, to the extent it exists, is largely based on his promise to reduce their tax bills and make it easier to bring in overseas cash.